What's in Meiji Seika Pharma Co., Ltd.'s pipeline?

Meiji Seika Pharma Co., Ltd. has 9 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 5 in Phase 1.

Which companies overlap with Meiji Seika Pharma Co., Ltd.'s portfolio?

Top competitors by shared drug class: , Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/meiji-seika-pharma-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Meiji Seika Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meiji Seika Pharma Co., Ltd. pipeline: 1 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Daunorubicin Hydrochloride	daunorubicin	marketed	Anthracycline Topoisomerase Inhibitor	Histone deacetylase 6	Oncology	1979-01-01
Matching Vehicle Solution	Matching Vehicle Solution	phase 3

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Meiji Seika Pharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). Meiji Seika Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/meiji-seika-pharma-co-ltd. Accessed 2026-05-17.